Does the media favor MRNA or PTGX?

In the previous week, Moderna had 36 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 40 mentions for Moderna and 4 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.09 beat Moderna's score of 0.40 indicating that Protagonist Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 17 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 10 Negative mention(s) 0 Very Negative mention(s) Neutral Protagonist Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PTGX or BNTX?

In the previous week, Protagonist Therapeutics had 1 more articles in the media than BioNTech. MarketBeat recorded 4 mentions for Protagonist Therapeutics and 3 mentions for BioNTech. Protagonist Therapeutics' average media sentiment score of 1.09 beat BioNTech's score of 0.85 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioNTech 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PTGX or ROIV?

In the previous week, Roivant Sciences had 5 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 9 mentions for Roivant Sciences and 4 mentions for Protagonist Therapeutics. Roivant Sciences' average media sentiment score of 1.49 beat Protagonist Therapeutics' score of 1.09 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Roivant Sciences 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PTGX or INSM?

In the previous week, Insmed had 9 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 13 mentions for Insmed and 4 mentions for Protagonist Therapeutics. Insmed's average media sentiment score of 1.32 beat Protagonist Therapeutics' score of 1.09 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insmed 10 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor VTRS or PTGX?

In the previous week, Protagonist Therapeutics had 1 more articles in the media than Viatris. MarketBeat recorded 4 mentions for Protagonist Therapeutics and 3 mentions for Viatris. Protagonist Therapeutics' average media sentiment score of 1.09 beat Viatris' score of 0.48 indicating that Protagonist Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Protagonist Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Protagonist Therapeutics (PTGX) Competitors

$118.96 +3.93 (+3.42%)

As of 04:00 PM Eastern

Compare

PTGX vs. MRNA, BNTX, ROIV, INSM, and VTRS

Should you buy Protagonist Therapeutics stock or one of its competitors? MarketBeat compares Protagonist Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Protagonist Therapeutics include Moderna (MRNA), BioNTech (BNTX), Roivant Sciences (ROIV), Insmed (INSM), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry.

How does Protagonist Therapeutics compare to Moderna?

Moderna (NASDAQ:MRNA) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations.

Moderna has a net margin of -143.55% compared to Protagonist Therapeutics' net margin of -154.88%. Protagonist Therapeutics' return on equity of -17.76% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%

75.3% of Moderna shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 10.8% of Moderna shares are owned by insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Moderna currently has a consensus price target of $36.60, indicating a potential downside of 40.00%. Protagonist Therapeutics has a consensus price target of $115.21, indicating a potential downside of 3.15%. Given Protagonist Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protagonist Therapeutics is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

Protagonist Therapeutics has lower revenue, but higher earnings than Moderna. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$2.20B	10.98	-$2.82B	-$8.15	N/A
Protagonist Therapeutics	$74.06M	103.30	-$130.15M	-$1.81	N/A

In the previous week, Moderna had 36 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 40 mentions for Moderna and 4 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.09 beat Moderna's score of 0.40 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	17 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	10 Negative mention(s)	0 Very Negative mention(s)	Neutral
Protagonist Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Moderna has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.86, meaning that its stock price is 86% more volatile than the broader market.

Summary

Protagonist Therapeutics beats Moderna on 12 of the 17 factors compared between the two stocks.

How does Protagonist Therapeutics compare to BioNTech?

Protagonist Therapeutics (NASDAQ:PTGX) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

Protagonist Therapeutics has higher earnings, but lower revenue than BioNTech. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$74.06M	103.30	-$130.15M	-$1.81	N/A
BioNTech	$3.25B	7.06	-$1.29B	-$5.88	N/A

In the previous week, Protagonist Therapeutics had 1 more articles in the media than BioNTech. MarketBeat recorded 4 mentions for Protagonist Therapeutics and 3 mentions for BioNTech. Protagonist Therapeutics' average media sentiment score of 1.09 beat BioNTech's score of 0.85 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioNTech	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Protagonist Therapeutics presently has a consensus price target of $115.21, suggesting a potential downside of 3.15%. BioNTech has a consensus price target of $129.56, suggesting a potential upside of 42.97%. Given BioNTech's higher possible upside, analysts plainly believe BioNTech is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

BioNTech has a net margin of -44.39% compared to Protagonist Therapeutics' net margin of -154.88%. BioNTech's return on equity of -5.30% beat Protagonist Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
BioNTech	-44.39%	-5.30%	-4.62%

Protagonist Therapeutics has a beta of 1.86, suggesting that its stock price is 86% more volatile than the broader market. Comparatively, BioNTech has a beta of 1.33, suggesting that its stock price is 33% more volatile than the broader market.

98.6% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 5.2% of Protagonist Therapeutics shares are owned by company insiders. Comparatively, 19.2% of BioNTech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Protagonist Therapeutics beats BioNTech on 8 of the 15 factors compared between the two stocks.

How does Protagonist Therapeutics compare to Roivant Sciences?

Protagonist Therapeutics (NASDAQ:PTGX) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

Protagonist Therapeutics has a net margin of -154.88% compared to Roivant Sciences' net margin of -3,629.19%. Protagonist Therapeutics' return on equity of -17.76% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
Roivant Sciences	-3,629.19%	-20.54%	-19.43%

98.6% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 5.2% of Protagonist Therapeutics shares are owned by insiders. Comparatively, 10.8% of Roivant Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Protagonist Therapeutics presently has a consensus target price of $115.21, suggesting a potential downside of 3.15%. Roivant Sciences has a consensus target price of $33.59, suggesting a potential upside of 4.29%. Given Roivant Sciences' higher probable upside, analysts clearly believe Roivant Sciences is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Protagonist Therapeutics has a beta of 1.86, suggesting that its stock price is 86% more volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market.

Protagonist Therapeutics has higher revenue and earnings than Roivant Sciences. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$74.06M	103.30	-$130.15M	-$1.81	N/A
Roivant Sciences	$8.26M	2,804.80	-$299.77M	-$0.60	N/A

In the previous week, Roivant Sciences had 5 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 9 mentions for Roivant Sciences and 4 mentions for Protagonist Therapeutics. Roivant Sciences' average media sentiment score of 1.49 beat Protagonist Therapeutics' score of 1.09 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Roivant Sciences	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Protagonist Therapeutics beats Roivant Sciences on 10 of the 17 factors compared between the two stocks.

How does Protagonist Therapeutics compare to Insmed?

Protagonist Therapeutics (NASDAQ:PTGX) and Insmed (NASDAQ:INSM) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.

Protagonist Therapeutics currently has a consensus price target of $115.21, suggesting a potential downside of 3.15%. Insmed has a consensus price target of $211.86, suggesting a potential upside of 107.40%. Given Insmed's stronger consensus rating and higher probable upside, analysts plainly believe Insmed is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96

Insmed has a net margin of -144.44% compared to Protagonist Therapeutics' net margin of -154.88%. Protagonist Therapeutics' return on equity of -17.76% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
Insmed	-144.44%	-130.11%	-51.57%

Protagonist Therapeutics has higher earnings, but lower revenue than Insmed. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$74.06M	103.30	-$130.15M	-$1.81	N/A
Insmed	$606.42M	36.51	-$1.28B	-$5.75	N/A

Protagonist Therapeutics has a beta of 1.86, meaning that its share price is 86% more volatile than the broader market. Comparatively, Insmed has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market.

In the previous week, Insmed had 9 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 13 mentions for Insmed and 4 mentions for Protagonist Therapeutics. Insmed's average media sentiment score of 1.32 beat Protagonist Therapeutics' score of 1.09 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insmed	10 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

98.6% of Protagonist Therapeutics shares are owned by institutional investors. 5.2% of Protagonist Therapeutics shares are owned by insiders. Comparatively, 2.1% of Insmed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Protagonist Therapeutics and Insmed tied by winning 8 of the 16 factors compared between the two stocks.

How does Protagonist Therapeutics compare to Viatris?

Viatris (NASDAQ:VTRS) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Viatris presently has a consensus target price of $17.50, suggesting a potential upside of 11.11%. Protagonist Therapeutics has a consensus target price of $115.21, suggesting a potential downside of 3.15%. Given Viatris' higher possible upside, equities research analysts clearly believe Viatris is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

Viatris has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.86, suggesting that its share price is 86% more volatile than the broader market.

Viatris has a net margin of -2.04% compared to Protagonist Therapeutics' net margin of -154.88%. Viatris' return on equity of 19.04% beat Protagonist Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.04%	19.04%	7.62%
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%

Protagonist Therapeutics has lower revenue, but higher earnings than Viatris. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Viatris, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.28	-$3.51B	-$0.26	N/A
Protagonist Therapeutics	$74.06M	103.30	-$130.15M	-$1.81	N/A

79.9% of Viatris shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 0.3% of Viatris shares are held by company insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Protagonist Therapeutics had 1 more articles in the media than Viatris. MarketBeat recorded 4 mentions for Protagonist Therapeutics and 3 mentions for Viatris. Protagonist Therapeutics' average media sentiment score of 1.09 beat Viatris' score of 0.48 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Protagonist Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Protagonist Therapeutics beats Viatris on 10 of the 17 factors compared between the two stocks.

Get Protagonist Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PTGX vs. The Competition

Export

Metric	Protagonist Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.65B	$3.45B	$6.47B	$12.11B
Dividend Yield	N/A	2.32%	2.68%	5.81%
P/E Ratio	-65.72	20.09	24.71	24.00
Price / Sales	103.30	298.47	521.51	102.74
Price / Cash	N/A	56.54	27.92	37.84
Price / Book	12.10	8.28	10.82	6.53
Net Income	-$130.15M	$23.85M	$3.56B	$336.99M
7 Day Performance	7.52%	5.21%	1.67%	-0.22%
1 Month Performance	19.93%	2.19%	0.43%	0.77%
1 Year Performance	122.94%	60.99%	32.84%	31.57%

Protagonist Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PTGX Protagonist Therapeutics	1.2739 of 5 stars	$118.96 +3.4%	$115.21 -3.1%	+115.7%	$7.65B	$74.06M	N/A	120	Positive News
MRNA Moderna	1.2423 of 5 stars	$63.96 flat	$36.60 -42.8%	+129.2%	$25.38B	$1.94B	N/A	4,700	High Trading Volume
BNTX BioNTech	4.5365 of 5 stars	$90.89 flat	$129.56 +42.5%	-15.3%	$22.98B	$3.25B	N/A	7,807
ROIV Roivant Sciences	1.8735 of 5 stars	$31.43 flat	$33.59 +6.9%	+172.9%	$22.61B	$8.26M	N/A	860	Positive News
INSM Insmed	3.4857 of 5 stars	$95.70 -0.1%	$211.86 +121.4%	-4.0%	$20.76B	$606.42M	N/A	1,664	Positive News High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PTGX) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Protagonist Therapeutics (PTGX) Competitors

PTGX vs. MRNA, BNTX, ROIV, INSM, and VTRS

How does Protagonist Therapeutics compare to Moderna?

Summary

How does Protagonist Therapeutics compare to BioNTech?

Summary

How does Protagonist Therapeutics compare to Roivant Sciences?

Summary

How does Protagonist Therapeutics compare to Insmed?

Summary

How does Protagonist Therapeutics compare to Viatris?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTGX vs. The Competition

Protagonist Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Protagonist Therapeutics (PTGX) Competitors

PTGX vs. MRNA, BNTX, ROIV, INSM, and VTRS

How does Protagonist Therapeutics compare to Moderna?

Is MRNA or PTGX more profitable?

Do institutionals & insiders have more ownership in MRNA or PTGX?

Do analysts rate MRNA or PTGX?

Which has better valuation & earnings, MRNA or PTGX?

Does the media favor MRNA or PTGX?

Which has more volatility and risk, MRNA or PTGX?

Summary

How does Protagonist Therapeutics compare to BioNTech?

Which has better earnings & valuation, PTGX or BNTX?

Does the media prefer PTGX or BNTX?

Do analysts rate PTGX or BNTX?

Is PTGX or BNTX more profitable?

Which has more risk and volatility, PTGX or BNTX?

Do institutionals and insiders hold more shares of PTGX or BNTX?

Summary

How does Protagonist Therapeutics compare to Roivant Sciences?

Is PTGX or ROIV more profitable?

Do institutionals & insiders hold more shares of PTGX or ROIV?

Do analysts rate PTGX or ROIV?

Which has more volatility and risk, PTGX or ROIV?

Which has higher valuation & earnings, PTGX or ROIV?

Does the media prefer PTGX or ROIV?

Summary

How does Protagonist Therapeutics compare to Insmed?

Do analysts recommend PTGX or INSM?

Is PTGX or INSM more profitable?

Which has preferable earnings and valuation, PTGX or INSM?

Which has more risk & volatility, PTGX or INSM?

Does the media prefer PTGX or INSM?

Do insiders & institutionals hold more shares of PTGX or INSM?

Summary

How does Protagonist Therapeutics compare to Viatris?

Do analysts prefer VTRS or PTGX?

Which has more risk & volatility, VTRS or PTGX?

Is VTRS or PTGX more profitable?

Which has better earnings and valuation, VTRS or PTGX?

Do insiders and institutionals hold more shares of VTRS or PTGX?

Does the media favor VTRS or PTGX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTGX vs. The Competition

Protagonist Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools